PERRIGO Co plc
PERRIGO Co plc (PRGO): 28 pipeline candidates · 2 upcoming catalysts · ~28 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
28.1 months
D/E 2.19 · 0% dilution
Lead: Approved
28 candidates
2 upcoming, next in ~25d
N/A
A transparent, data-derived signal for PERRIGO Co plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.4B
Cash
$357.2M
Quarterly Burn
$113.6M
Runway
28.1 mo
Revenue
$969.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (28 candidates)
| Drug | Phase |
|---|---|
| acetaminophen | Approved |
| aco | Approved |
| cetirizine hydrochloride allergy | Approved |
| compeed | Approved |
| desloratadine | Approved |
| diclofenac | Approved |
| diclofenac | Approved |
| ellaone | Approved |
| esomeprazole magnesium | Approved |
| famotidine | Approved |
Showing 10 of 28 candidates. Sign up for full pipeline.
Upcoming Catalysts (2)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
328
Total value held
$1.44B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 17,120,084 | $183.9M |
| vanguard capital management llc | 12,419,074 | $133.4M |
| neuberger berman group llc | 10,460,080 | $112.3M |
| vanguard portfolio management llc | 8,141,919 | $87.4M |
| fuller & thaler asset management, inc. | 7,662,883 | $82.3M |
| state street corp | 7,225,395 | $77.6M |
| dimensional fund advisors lp | 6,567,616 | $70.5M |
| millennium management llc | 4,279,731 | $46.0M |
| menora mivtachim holdings ltd. | 3,872,000 | $41.6M |
| morgan stanley | 2,776,642 | $29.8M |
Showing top 10 of 328 institutional holders of PERRIGO Co plc. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in PERRIGO Co plc's pipeline?
PERRIGO Co plc (PRGO) has 28 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PERRIGO Co plc's lead drug candidate?
PERRIGO Co plc's most advanced tracked candidate is acetaminophen (Approved).
What is PERRIGO Co plc's next catalyst?
PERRIGO Co plc's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: OPILL" — expected July 13, 2026.
What is PERRIGO Co plc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PERRIGO Co plc has approximately 28.1 months of cash runway.
What is PERRIGO Co plc's market capitalization?
PERRIGO Co plc's market capitalization is approximately $1.4B.
Get the full picture on PERRIGO Co plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.